Generics

OXFORD, England  — Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by Design, on Tuesday announced that it has entered into a global licensing agreement with Mylan for its leading inhaled respiratory products, PSX1001 and PSX1050.

PARSIPPANY, N.J. — Total spending on U.S. medicines increased 1% on a real per capita basis in 2013, while the use of healthcare services overall rose for the first time in three years, according to a new report issued today by the IMS Institute for Healthcare Informatics.

PITTSBURGH — Mylan announced that it has launched eszopiclone tablets in 1 mg, 2 mg and 3 mg form. The drug — which is used for the treatment of insomnia — is the generic version of Lunesta from Sunovion Pharmaceuticals.

Mylan received final approval from the Food and Drug Administration for its abbreviated new drug application. Eszopiclone tablets had sales in the U.S. of approximately $851.8 million for the 12 months ending Dec 31, 2013, according to IMS Health.

PEAPACK, N.J. — Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products. The drug is the authorized generic versions of Caduet.

DUBLIN — Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).

Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending abbreviated new drug application beginning on April 1, 2015.

MOUNT PROSPECT, Ill. — Now available online, the Drug Enforcement Administration National Prescription Drug Take-Back Day collection site locator allows consumers to search for a nearby location to dispose of unneeded medications on Saturday, April 26, 2014, the National Association of Boards of Pharmacy announced Wednesday. On April 26, from 10 a.m.

PITTSBURGH — Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg. This product is the generic version of Frova, which is used to treat acute migraine headaches in adults. 

SCOTTSDALE, Ariz. — NCPDP, the not-for-profit pharmacy standards development organization, on Wednesday announced the availability of a patient safety white paper that provides specific industry guidance for standardizing the dosing designations and labeling of oral liquid medications.